WithdrawnPhase 4

Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure

Stopped: No patients enrolled

United States0Started 2018-05-01

Plain-language summary

Single center, prospective, randomized, non-blinded research study comparing intravenous vasodilator infusion vs. inotropic infusion in patients admitted to the hospital or in the emergency room at Montefiore Medical Center presenting with the diagnosis of acute decompensated systolic heart failure with low cardiac output but no hypotensive.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Persistent dyspnea or orthopnea or edema at screening and at the time or randomization, despite standard background therapy for heart failure.
✓. Pulmonary congestion on chest radiograph.
✓. N-terminal pro b-type natriuretic peptide (NT-proBNP) ≥ 2000 pg/ml; for patients ≥ 75 years old or with current atrial fibrillation, NT-proBNP ≥ 3000 pg/ml.

What they're measuring

Arrhythmia incidence

Timeframe: within 72 hours after the initiation of the drug

Serum troponin T release

Timeframe: within 72 hours after the initiation of the drug

Hypotension incidence

Timeframe: within 72 hours after the initiation of the drug

Trial details

NCT IDNCT02767024

SponsorMontefiore Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-05-01

View on ClinicalTrials.gov More Acute Heart Failure trials